Lidocaina Cloridrato Monico

Lidocaine, the active ingredient in Lidocaina Cloridrato Monico, is a local anesthetic (amide type) presented as a sterile injectable solution for intravenous use. It provides reversible nerve impulse blockade for minor surgical procedures, regional nerve blocks, and ventricular arrhythmia management in adult patients.

GNH USA supplies Lidocaina Cloridrato Monico as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU GMP standards and provides reliable logistics for clinical and institutional customers. Products are shipped with full documentation to meet regulatory requirements across regions.

Lidocaine is employed in clinical settings to achieve local anesthesia and to control certain cardiac arrhythmias.

Minor surgical procedures: provides rapid onset surface anesthesia for incision and suturing. Peripheral nerve blocks: enables regional anesthesia for limb surgeries and pain control. Ventricular arrhythmias: stabilizes cardiac electrical activity during acute episodes.

Lidocaine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Transient tingling or numbness at the injection site - Mild dizziness or light‑headedness - Nausea or metallic taste

Serious or Rare Side Effects: - Anaphylactic reaction with rash, bronchospasm or shock - Cardiac conduction disturbances (bradycardia, heart block, ventricular arrhythmia) - Central nervous system toxicity (seizures, confusion, loss of consciousness)

When using lidocaine, clinicians should observe several safety measures. - Dose adjustment: individualize dose based on patient weight, cardiac status and concomitant medications - Cardiovascular monitoring: observe heart rate and rhythm during IV administration - Avoid rapid bolus: administer slowly to reduce risk of CNS toxicity - Use with caution in patients with hepatic impairment - Avoid in patients with known hypersensitivity to amide local anesthetics - Store at ambient temperature: keep in original container, protect from light and moisture

Lidocaine can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): additive cardiac conduction effects - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lidocaine plasma levels - Beta‑blockers: may enhance bradycardia

Moderate Interactions (Monitor Closely): - Class II antiarrhythmics (e.g., amiodarone): may increase toxicity - General anesthetics (e.g., propofol, volatile agents): synergistic CNS depression - Diuretics (e.g., furosemide): may alter plasma protein binding